Fate Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Fate Therapeutics

08/08/2023 23:05

* Fate Therapeutics Inc  FATE.OQ  reported a quarterly
adjusted
loss of 54 cents​​ per share for the quarter ended in June. The
mean expectation of twenty two analysts for the quarter was
for a loss of 59 cents per share.
    * Revenue fell 95% to $933.00 thousand from a year ago;
analysts
expected $5.53 million. 
    * Fate Therapeutics Inc's reported EPS for the quarter was a
loss
of 54 cents​.
    * The mean earnings estimate of analysts had risen by
about 1.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Fate Therapeutics Inc shares had fallen by 25.4% this
quarter and lost 64.8% so far this year.
    * The company reported a quarterly loss of $52.76 million.
    * Wall Street's median 12-month price target for Fate
Therapeutics
Inc is $7.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 14
"hold" and 2 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 8 at 10:05 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.59          -0.54          Beat
 Mar. 31 2023      -0.62          -0.19          Beat
 Dec. 31 2022      -0.86          -0.58          Beat
 Sep. 30 2022      -0.89          -0.86          Beat